Posted 23 October, 2023

Abivax S.A. IPO completed

IPO completed detected for ticker Nasdaq:ABVX in a 424B4 filed on 23 October, 2023.

  This is our initial public offering of our ADSs in the United States.  

Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Abivax S.A.
Health Care/Life Sciences • Pharmaceuticals
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Market Cap
View Company Details